Bioceros is one of the worlds’ premier provider of services related to preclinical development of monoclonal antibodies, generation of GMP-ready protein producing cell lines and mass spectrometry based bio-analytics. Bioceros’ preclinical services are available on a modular basis, fully adjustable to clients’ requests. Together with the other divisions of the Polpharma Group, we can offer a completely integrated program from DNA to Drug Product.

We can provide our customers with world class development capabilities and a capacity for industrial-scale supply, enabling them to advance their medicinal product and help patients in need.

The people at Bioceros strongly believe that true and close collaboration speeds up selection and development of clients’ most viable drug candidates. At the same time, it helps move the company’s own portfolio forward. The company’s commitment extends was beyond just putting a high-yield stable cell line together; first and foremost, Bioceros is dedicated to improve the lives of patients and, through its efforts, to provide opportunities for real market growth.